Federal contract award
75A50122C00015
DIAZYME: FINALIZE DESIGN VERIFICATION, OBTAIN REGULATORY APPROVAL (EUA AND 510K), SCALE UP PRODUCTION AND DEPLOY THE DIAZYME SARS-COV-2 NEUTRALIZING ANTIBODY CLIA KIT.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $3.2M |
| Current contract value | $3.2M |
| Potential contract value / ceiling | $3.2M |
| Start date | Aug 1, 2022 |
| Current end date | Sep 30, 2025 |
| Potential end date | Sep 30, 2025 |
| Latest award activity | Jul 8, 2025 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 6 of 6 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jul 8, 2025 | P00005 | $-600.0K | EOI::EO: PRESIDENTIAL COST SAVINGS INITIATIVES::EOI BILATERAL MODIFICATION TO DE-OBLIGATE $600,000.00 FROM CLIN 0001. |
| Jun 27, 2025 | P00004 | $0 | EOI:: PRESIDENTIAL COST SAVINGS INITIATIVES ON OR AFTER JANUARY 20, 2025 EOI NOTICE OF TERMINATION FOR CONVENIENCE. |
| Dec 23, 2024 | P00003 | $0 | THE PURPOSE OF THIS NOT COST MODIFICATION IS TO EXTEND THE PERIOD OF PERFORMANCE FOR CLIN 001 FROM 12/31/2024 THROUGH 9/30/2025. |
| Oct 29, 2024 | P00002 | $0 | THE PURPOSE OF THIS NOT COST MODIFICATION IS TO EXTEND THE PERIOD OF PERFORMANCE AND REVISE KEY PERSONNEL. |
| Jul 30, 2024 | P00001 | $0 | THE PURPOSE OF THIS NOT COST MODIFICATION IS TO EXTEND THE PERIOD OF PERFORMANCE AND REVISE KEY PERSONNEL. |
| Aug 1, 2022 | 0 | $3.8M | DIAZYME: FINALIZE DESIGN VERIFICATION, OBTAIN REGULATORY APPROVAL (EUA AND 510K), SCALE UP PRODUCTION AND DEPLOY THE DIAZYME SARS-COV-2 NEUTRALIZING ANTIBODY CLIA KIT. |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.